市場調查報告書
商品編碼
1504238
胰島素筆針的市場規模,佔有率,預測,趨勢:各類型,各糖尿病類型,不同流通管道,醫療保健環境-2031年為止的世界預測Insulin Pens Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Smart [Bluetooth, NFC]) Diabetes Type (Type 1, Type 2) Distribution (Hospital, Retail Pharmacies, E-commerce) Healthcare Setting - Global Forecast to 2031 |
預計到 2031 年,全球胰島素筆市場將超過 67.3 億美元,2024 年至 2031 年複合年增長率為 6.7%。
該報告在廣泛的二級和一級研究以及對市場情景的深入分析後,對主要市場驅動因素、限制因素、課題和機會進行了分析。成長因素包括糖尿病盛行率的增加、胰島素筆的技術進步、自我給藥需求的增加、糖尿病意識計畫的不斷發展。然而,胰島素筆的高成本、胰島素筆替代品的可用性以及患者對針頭的恐懼限制了該市場的成長。
此外,人們對胰島素筆的偏好超過了小瓶和注射器,新興經濟體以及胰島素製造商之間的聯盟和合作預計將為該市場的參與者提供成長機會。然而,新興國家缺乏意識和知識以及發展中國家獲得醫療保健的機會有限是影響市場成長的主要課題。
(註:為前 5 名公司提供 SWOT 分析)
Insulin Pens Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Smart [Bluetooth, NFC]) Diabetes Type (Type 1, Type 2) Distribution (Hospital, Retail Pharmacies, E-commerce) Healthcare Setting-Global Forecast to 2031
The global insulin pens market is projected to reach over $6.73 billion by 2031 at a CAGR of 6.7% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the increasing prevalence of diabetes, technological advancements in insulin pens, rising demand for self-administration of drugs, and rising diabetes awareness programs. However, the high cost of insulin pens, the availability of alternatives to insulin pens, and needle anxiety in patients restrain the growth of this market.
Furthermore, the rising preference for insulin pens over vials and syringes, emerging economies, and partnerships and collaborations by insulin manufacturing companies are expected to generate growth opportunities for the players operating in this market. However, lack of awareness and knowledge in developing countries and limited access to healthcare in developing countries are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global insulin pens market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Biocon Limited (India), Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), Owen Mumford Limited (U.K.), Medtronic plc (Ireland), Emperra GmbH E-Health Technologies (Germany), pendiq GmbH (Germany), and Jiangsu Delfu medical device Co., Ltd (China).
Among all the types studied in this report, the disposable insulin pens segment is projected to register the highest CAGR of over 7.0% during the forecast period of 2024-2031. The high growth of this segment is attributed to the benefits offered by disposable insulin pens, such as their ability to cause less pain during administration. They come with a prefilled insulin cartridge loaded into the pen, and the entire product can be discarded after the cartridge is finished, minimizing the chances of infections.
Among all the applications studied in this report, in 2024, the type 1 diabetes segment is expected to account for the largest share of the insulin pens market. The large market share can be attributed to the increasing number of insulin-dependent patients and the rising number of type 1 diabetes cases. For instance, according to the International Diabetes Federation (IDF) data, in 2022, 8.75 million lived with type 1 diabetes globally. Out of which 1.52 million of these people were under 20 years old. Thus, the increasing number of type 1 diabetes cases drives the growth of this segment.
Among all the distribution channels studied in this report, in 2024, the distribution channel segment is expected to account for the largest share of the insulin pens market. Retail pharmacies often stock a diverse selection of insulin pens of different types. The increasing consumer demand for insulin pens and the opportunity for customers to inspect the product before making a purchase are the factors driving the growth of this segment.
Among all the healthcare settings studied in this report, in 2024, the home care segment is expected to account for the largest share of over 51.2% of the insulin pens market. The large market share of this segment can be attributed to the increasing development and adoption of home care devices due to their convenience, precision, and accuracy. Additionally, there has been a growing focus among companies to raise awareness about diabetes, which has led to increased adoption of insulin pens in home care settings.
An in-depth analysis of the geographical scenario of the global insulin pens market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 37.8% of the insulin pens market. In the region in 2024, the U.S. is expected to account for the largest share of the insulin pens market in North America. The large share of the country is attributed to the presence of major insulin pen companies such as Eli Lilly and Company (U.S.) and Becton, Dickinson and Company (U.S.), increasing healthcare expenditure, rising demand for self-administration of drugs, and rising number of diabetes cases in this region are some of the major factors driving the growth of the region.
Insulin Pens Market Assessment-by Type
Insulin Pens Market Assessment-by Application
Insulin Pens Market Assessment-by Distribution Channel
Insulin Pens Market Assessment-by Healthcare Setting
Insulin Pens Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)